美联储威廉姆斯：判断货币政策的限制性程度是很困难的。

Shanghai RAAS said on Sept. 28 it is pursuing the purchase of a CDMO plant held by Boehringer Ingelheim Biopharmaceuticals (China) as a "strategic positioning" move to close gaps in its innovative-drug industrialization capability. Vice chairman and general manager Xu Jun said the company's push into innovative drugs is not a "do-or-die" gamble; R&D will be funded by stable cash flow from its blood-products business, via rolling, measured investments, and the company will not channel all blood-products profits into innovative drugs at once.

德意志银行：将奈飞(NFLX.O)评级从持有上调至买入；将目标价从100美元下调至95美元。